SuperworthRallybio RLYB
- Market cap
- $88.4M
- PE
- n/m
- not a meaningful number
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 137×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $646K
- −15% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- n/m
- not a meaningful number
Rallybio trades at 137× sales. Revenue was $646K over the last twelve months, down 15% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | n/a | $0 | $299K | $299K | $38K | $212K | $212K−29% | $212K−29% | $222K+484% | $212K+0% | $0 | |
| R&D | $13.3M+10% | $15.9M+48% | $12.9M+16% | $12.9M−1% | $8.2M−38% | $7.4M−54% | $5.7M−56% | $6.1M−53% | $4.1M−50% | $3.7M−51% | $2.9M−50% | $758K−88% |
| SG&A | $6.1M−10% | $5.2M−18% | $6.9M−5% | $4.4M−37% | $4.1M−32% | $4.3M−18% | $4.2M−39% | $4.2M−4% | $3M−27% | $3M−30% | $6.1M+46% | $4.9M+17% |
| −$19.4M+3% | −$21.1M+24% | −$19.8M+8% | −$17M−15% | −$12.1M−38% | −$11.6M−45% | −$9.7M−51% | −$10.1M−41% | −$6.9M−43% | −$6.4M−45% | −$8.7M−10% | −$5.7M−44% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | −$17.7M−3% | −$19.6M+23% | −$18.3M+10% | −$15.7M−15% | −$10.8M−39% | −$10.6M−46% | −$8.9M−52% | −$9.4M−40% | $16M | −$5.9M−45% | −$8.3M−7% | $45M |
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | $0 | n/a | n/a | n/a | $1.3M | |
| Net income | −$18.4M+0% | −$20.2M+25% | −$19M+10% | −$16.2M−13% | −$11.5M−38% | −$11M−45% | −$9.4M−50% | −$9.7M−40% | $16M | −$5.9M−47% | −$8.3M−12% | $43.7M |
| −$3.60−25% | −$4.00+9% | −$3.76+9% | −$2.96−20% | −$2.08−42% | −$2.00−50% | −$1.69−55% | −$1.76−41% | $2.88 | −$1.03−49% | −$1.46−14% | $7.53 | |
| 5.1M+32% | 5.1M+14% | 5.1M+1% | 5.5M+9% | 5.6M+10% | 5.6M+10% | 5.6M+10% | 5.6M+2% | 5.6M+1% | 5.7M+2% | 5.7M+2% | 5.8M+3% |
R&D: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
SG&A: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Operating income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Income tax: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Net income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them. Q2 FY20 and Q2 FY21: not printed by the filing, worked out from its own lines.
EPS, diluted: 6 periods, Q1 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY20: share-days: the 6-month average less the second quarter's. Q4 FY20 and Q4 FY21: share-days: the 12-month average less the 9-month, weighted by days. 3 periods, Q4 FY22 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average over 365 days less the 9-month over 273, the two on one basis (x8).
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Rallybio's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| RLYBRallybio | $88.4M | n/m | n/a | 137× | −15% | n/m | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| ARVNArvinas | $477.3M | 45.6× | 52.3× | 1.5× | −15% | 2.9% | |
| PBYIPuma Biotechnology | $568.9M | 21.2× | 12.3× | 2.5× | −3% | 11.6% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.9× | 1.5× | +26% | 33.4% | |
| ZVRAZevra Therapeutics | $582.6M | 10.5× | 12.3× | 4.3× | +119% | 42.8% | |
| CRMDCorMedix | $611.9M | 3.7× | 4.0× | 1.3× | +281% | 40.5% | |
| COLLCollegium Pharmaceutical | $747.5M | 18.5× | 19.1× | 0.9× | +14% | 5.9% | |
| Peer median | $523.1M | 11.3× | 13.6× | 1.4× | +7% | 11.6% |
Investors who own it
Investors we follow who held Rallybio at the end of Jun 30, 2026, from their 13F filings.
- Andreas HalvorsenViking Global Investors0.0% of portfolio
More on Rallybio
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .